Previous studies using conventional heteroantisera and monoclonal antibodies (1, 2) have characterized the expression of a common acute lymphoblastic leukemia antigen (CALLA) 1 in various hematopoietic malignancies and normal tissues, CALLA has been demonstrated to be a 100,000-dahon glycoprotein that is expressed by leukemic cells from ~80% of patients with non-T acute lymphoblastic leukemia (ALL), 10% of patients with T-ALL, and 40% of patients with chronic myelocytic leukemia (CML) in blast crisis, as well as lymphoma cells from ~40% of patients with T cell lymphoblastic lymphomas and almost all Burkitt's lymphomas and nodular lymphomas (3) . Within the hematopoietic system, CALLA is also detected on a small population of mononuclear cells (1-3%) in either normal or regenerating bone marrow. Fetal hematopoietic organs contain a larger proportion of CALLA+ cells and mononuclear cell suspensions from fetal liver and fetal bone marrow have been found to contain 2-10% CALLA+ cells (2) (3) (4) (5) .
Although much is known about the distribution of CALLA, very little is known about its functional role on the cell surface or its appearance during ontogeny. Recent studies have demonstrated that CALLA belongs to a family of 100,000-dahon cell surface proteins that are widely expressed by hematopoietic cells (6) and is also present in some nonhematopoietic tissues (7) . In addition, binding of j5 monoclonal antibody to cell surface antigen results in the modulation of the expression of CALLA on 1 Abbreviations u~ed in thi~" paper: ALL, acute lymphoblastic leukemia: BM, bone marrow; C, complement; CALl,A, common acute lymphoblastic leukemia antigen; CFU~G/M, granulocytc/monocyte cotol~y forming unit; CML, chronic myelocytic leukemia; tyro-p,, intracytoplasmic g chain; FACS, fluorescence activated cell sorter: FCS, fetal calf serum: C,/Md"ITC, fluorescein-conjugated goat anti-mouse immunoglobulin; G/M-TRITC, rhodamine-col~iugated goat anti-mouse immunoglobulin; ItBSS, t tanks' balanced salts solution; MoAb, monoclonal antibodies; R/M-SRBC, rabbit anti-mouse Ig-coated sheep erythrocytes; SMEM + 2.5% AB, supplemented minimum cxsential medium with 2.5+;4, human AB: SRBC, sheep erytbrocytes; TdT, terminal transferase enzyme. 1 15 leukemic cells and cell lines. J5 modulation occurs in vitro (8) and in vivo (9) and results in a reversible and specific loss and internalization of cell surface CALLA (10) . Despite the analogous modulatory behavior of CALLA and known membrane receptors for various hormones, no functional role for CALLA has yet been defined.
Given the compelling data demonstrating that most tumors of myeloid and lymphoid systems reflect phenotypes of frozen stages of differentiation corresponding to their normal cellular counterparts, in this study we have purified normal fetal hematopoietic cells that express CALLA to further delineate the role of this cell surface glycoprotein in early lymphoid differentiation. Pure populations of CALLA+ cells were obtained by either immune rosetting or fluorescence-activated cell sorting, and these cells were subsequently characterized using dual fluorescence labeling techniques for the presence of specific cytoplasmic and surface markers. These data suggest that CALLA+ cells are committed lymphoid cells that are in the early stages of lymphoid differentiation and that, furthermore, normal CALLA+ cells appear to be the normal counterparts of CALLA+ lymphoblastic leukemia cells.
Materials and Methods

Preparation of Mononuclear Single Cell Suspensions from Fetal Tissues.
Fetal tissue specimens were obtained immediately after prostaglandin-or saline-induced abortions from fetuses with no apparent abnormalities. The age of the fetus was determined by measurements of crown-rump and foot lengths. Procurance of all specimens was approved by the Brigham and Women's Hospital Committee on the Use of Human Subjects in Research, Boston, MA.
Fetal bone marrow was obtained from femoral bones that were removed aseptically. Single cell suspensions were produced by flushing the intramedullary cavities with Hanks' balanced saline solution (HBSS). Fetal livers were minced into 1-cm 3 pieces and passed repeatedly in and out of a 20-cm ~ syringe until large clumps of cells were no longer visible. Subsequently, cells were passed through a cone-shaped nylon mesh to obtain single cell suspensions.
Single cell suspensions from both organs were then layered onto Ficoll-Hypaque (F/H) density gradients and after centrifugation the resulting interface cells were washed twice and resuspended in supplemented minimum essential medium with 2.5% pooled human AB serum (SMEM + 2.5% AB). For preparation of fetal liver mononuclear cell suspensions, this step was repeated to maximize elimination of erythrocytes.
Monoclonal Antibodies. The production and reactivities of the monoclonal antibodies (MoAb) used in this study have been described previously. A summary of the specificity of these reagents is presented in Table I .
Preparation of Rabbit Anti-Mouse tg-coated Sheep E~throcytes (R/M-SRBC).
As described previously (23), New Zealand white rabbits were immunized repeatedly with a mixture of MoAb including J2, J5, J13, MY7, and MYS. The immune serum was first passed through a column of human Ig coupled to Sepharose 4B (Pharmacia) and then through a column of mouse IgSepharose. Purified rabbit anti-mouse Ig was eluted from the second column with 1 M glycine buffer, pH 2.0, extensively dialyzed against 0.9% saline solution, adjusted to a concentration of 1 mg protein/ml, and stored at -20°C.
Sheep erythrocytes (SRBC), washed three times in saline, were coupled with the rabbit antimouse antiserum with CrCla as follows: 0.5 ml packed SRBC were mixed with 0.5 ml rabbit anti-mouse antiserum and 0.5 mI saline, whereupon 0.5 mt of freshly prepared CrCla solution (1 mg/ml) was added dropwise under vigorous stirring. After a 6-7-min incubation at room temperature, the reaction was stopped with cold phosphate-buffered saline and the coupled SRBC were washed three times in saline and resuspended to a 10% solution in SMEM + 2.5% AB.
Immune Rosette Depletion of Myeloid and E~ythroid Cells.
To deplete the mononuclear cell suspensions of erythroid and myeloid precursor cells, mononuclear cells from fetal bone marrow and fetal liver were incubated at 4°C for 30 min with a mixture of MoAb including: T9 (dilution 1:2,000), Mol (1:100), Mo2 (I:100), MY7 (1:100), and MY8 (1:100). After three washes in SMEM + 2.5% AB, the cells were resuspended to 1.0 ml and mixed with 1.0 ml of the 10% R/M-SRBC solution. When leukocyte cell numbers exceeded 200 X 10 ~, 1 3 ml of R/M-SRBC was used_ Using this method, up to 600 X 10 ~ cells can be processed in one tube. After a centrifugation at 180 g for 5 min, the rosette mixture was resuspended with a Pasteur pipette until clumps were no longer visible. The quality of the rosettes was determined under fluorescence microscopy in an acridine orange-stained aliquot; subsequently, the rosettes were layered on F/H and spun for 15 rain at 1,140 g. The resulting interface suspension (subsequently referred to as MoAb-rosette-negative cells) was harvested and washed, whereas the pellet (MoAb-rosette-positive cells) was recovered after lysis of SRBC with ammonium chloride buffer. The viability in each fraction was >90% and total recovery of cells was >60%.
Purification of CALLA + Cells by Rosette Sedimentation. CALLA+ cells were purified by a second rosette sedimentation after labeling of the MoAb-rosette-negative cell fractions with anti-CALLA antibodies. Pilot experiments with CALLA+ ALL lines (balm-1 and Laz 221) had shown that the rosetting efficiency could be increased by adding an IgM antibody, J13, which is also specific for CALLA, to J5 during the antibody-labeling procedure. Consequently, an equal mixture of J5 and J 13 (final dilution of each, 1 : 100) was used when the MoAb-roset renegative cell fraction was to be rosetted. Otherwise, the rosetting was performed as described above. Detection of Intracellular Antigens. The terminal transferase enzyme (TdT) was detected by a two-layer immunofluorescence assay on cytocentrifuged, methanol-fixed cells as described by Bollum (24) using a kit from Bethesda Research Laboratories (Rockville, MD). Intracytoplasmic /z (cyto-/t) was detected on cytocentrifuged, methanol-fixed smears using directly fluorescein-or rhodamine-conjugated rabbit anti-p chain antisera (kindly provided by Dr. M. D. Cooper, University of Alabama, Birmingham, AL). Nalm-1 cells were used as positive controls for the intracellular markers in the TdT assay and Raji cells in the cyto-# assay.
Purification of CALLA+ Cells by
Modulation In Vitro of the CALLA+ Cells. Antigenic modulation in vitro was induced in
MoAb-rosette-negative cell fractions by addition of monoclonal antibody and subsequent incubation for different periods of time at 37°C. Either J5 antibody, J0, or anti-Ia was added to identical cultures. To ensure antibody excess, 0.1 mg antibody per l0 s cells was used. Cell culture media consisted of RPMI 1640 supplemented with 10% fetal calf serum (FCS). After incubation, cells were washed twice and phenotyped as described above for the CALLA-cells.
Myeloid Precursor Cell (CFU-G/M) Assays.
CFU-G/M were assayed as described by Griffin et al. (23) by plating l0 s mononuclear cells/ml in Iscove's modified Dulbecco's minimal essential medium containing 20% FCS and 0.3% agar (Agar Noble; Difco, Detroit, MI), over a feeder layer of 1 × 106 peripheral blood leukocytes/ml in 0.5% agar. After 10 d of culture at 37°C in an atmosphere of 5% CO2 in humidified air, colonies (>40 cells) were enumerated using an inverted microscope.
Results
Purification of CALLA + Cells from Fetal Tissues. As shown in Fig. 1 A, mononuclear cells obtained from fetal bone marrow after F/H density gradient sedimentation primarily consisted of maturing myeloid cells. In contrast, mononuclear cells obtained from fetal liver (Fig. 1 E) after two F/H-purification steps consisted primarily of maturing erythroid precursors. However, in both cases these cells could be removed from the mononuclear cell suspensions by rosette sedimentation with a mixture of MoAb ( Fig. 1 B and F) . In contrast to the MoAb-rosette-positive fractions, the MoAb-
rosette-negative suspensions from both bone marrow (Fig. 1 C) and liver (Fig, 1 G) were remarkably similar, consisting of a mixture of small to medium-sized lymphocytes and large blast cells. When separating the MoAb-rosette-negative fraction further into C A L L A + and C A L L A -subsets, the large blast cells were found exclusively in the C A L L A -fraction (Fig. 1 D) , whereas the C A L L A + fraction consisted solely of lymphoid-appearing cells (Fig. 1 H) . After rosette depletion of mature myeloid cells, 40-90% of the cells in MoAb-rosettenegative bone marrow suspensions were C A L L A + . Further purification of C A L L A + cells was then accomplished by fluorescence-activated cell sorting using an EPICS V. A representative purification experiment is shown in Fig. 2 where the percentage of C A L L A + cells in the MoAb-rosette-negative subset was 85%; subsequent purification yieIded a population that was 98% C A L L A + .
To purify C A L L A + cells from fetal liver, an alternative method that was able to process larger numbers of cells was used. After two F / H sedimentations and rosette depletion of mature cells with a mixture of MoAb, the MoAb-rosette-negative fetal liver suspensions contained 20-60% C A L L A + cells. Subsequently, C A L L A + cells were purified from the MoAb-rosette-negative fraction by indirect immune rosetting with both J5 and J13 antibodies. Table II presents >95  45  NT  NT  NT  2211  >95  >95  >95  >95  >95  41  <5  NT  NT  2311  NT  >95  NT  >95  >95  52  NT  NT  NT   21  ¶  >95  >90  >95  >95  >95  31  <5  <5  <5  2211  >95  >95  >95  >95  >95  39  <5  <5  <5  23 ¶  >95  >95  >95  >95  >95  30  <5  <5  <5  24 ¶  NT  >90  NT  >95  >95  27 NT NT NT * Determined by fluorescence microscopy of J5+ cells incubated overnight at 37°C with G/M-FITC to obtain capping and subsequently stained with a second monoclonal antibody and G/M-TRITC. :~ Labeled with biotin-conjugated B 1 followed by rhodamine-labeled avidin. § Labeled simultaneously with both monoclonal antibodies noted.
11 Purified from MoAb-rosette-negative cell fractions by cell sorting. ¶ Purified from MoAb-rosette-negative ceil fractions by J5 rosette sedimentation. ** Not tested.
G/M-FITC to the latter) allowed for the definition of other cell surface antigens on these cells by a second monoclonal antibody and G/M-TRITC.
The results from a series of experiments with both fetal bone marrow and fetal liver of different ages are given in Table III . Although these cells have been isolated from different tissues by two different methods, the cells displayed similar cell surface antigens. The purity of each suspension, as judged by the presence of J5-FITC caps, exceeded 90% in every instance. It should also be noted that addition of more J5 antibody and G/M-TRITC did not give any additional fluorescence, indicating that all of the J5 surface antigen was located within the G/M-FITC cap and that these cells had not synthesized more CALLA during the overnight culture. Further analysis with J13 antibody, which is also specific for CALLA, showed that nearly all the cells bound J13 within the J5-FITC caps. There was also no appreciable cell surface staining with J13 antibody other than that found in the J5 caps.
Three antigens, Ia, J2, and T10, were found on virtually all the CALLA+ cells. In contrast to the reactivity pattern seen with J13, these antigens were uniformly distributed along the cell membrane and were distinct from CALLA. The B 1 antigen, in contrast, was only found on a fraction of the CALLA+ cells, and, when present, was uniformly distributed on the cell surface. Very few CALLA+ cells were reactive with anti-myeloid or T cell antibodies. Thus, virtually all CALLA+ fetal bone marrow and liver cells were J2+, Ia+, T10+, MY7/8-, T3/9/11-, whereas 30-50% expressed B 1.
The phenotype of the CALLA-cells obtained after J5/J13 rosette sedimentation of MoAb-rosette-negative fractions was determined by indirect immunofluorescence with subsequent analysis on a FACS-I. As shown in Table IV , these cells have been effectively depleted of CALLA+ cells, as judged by the low numbers of cells reactive with the J5 and J13 antibodies. Likewise, very few myeloid or mature T cells were found. On the other hand, significant percentages of these cells expressed Tl0. In contrast to the analysis of CALLA+ cells, only a minority of the CALLA-cells were reactive with either J2 or anti-B1.
The CALLA+ and CALLA-populations were also analyzed for the presence of nuclear TdT and cyto-~ after methanol fixation. As shown in Table V , 10-30°7c of the CALLA+ cells express cyto-/t chains, but this marker is not restricted to the CALLA+ subset because 10-15% of CALLA-cells also contain cyto-/*. Furthermore, the finding of cyto-/~+ cells within the CALLA-subset correlates rather closely with the den> onstration of 11-17% B 1+ cells within this population (Table IV) . When expression of TdT was examined, it was found that 5-25% of CALLA+ cells exhibited a nuclear TdT staining pattern. In the CALLA-population, a somewhat higher percentage of cells (35-50%) was TdT positive. In further experiments, biotin-labeled B1 and rhodamine-avidin were combined with the intracellular markers in CALLA+ cells. As summarized in Table VI , it was determined that nearly all of the B 1+ cells were found in the TdT-subset and that the cyto-/x+ cells were a subset of the B 1 + cells. This suggests that there is very little overlap between subsets expressing either TdT or cyto-# within CALLA+ fetal cells.
Modulation of CALLA Expression. Previous studies using leukemic cells and cell lines
have demonstrated that binding of J5 monoclonal antibody to cell surface CALLA results in the specific modulation of this cell surface antigen. We were therefore interested in evaluating the relevance of this phenomenon using nonmalignant CALLA+ ceils. MoAb-rosette-negative bone marrow (BM) suspensions highly enriched for CALLA+ cells were incubated for various periods of time with either J0 (ascites from a nonreactive hybridoma), J5, or anti-Ia, which has previously been shown not to modulate Ia antigen expression (8) . As can be seen in Fig. 3 A, 65% of the unmodulated cells were CALLA+ and 85% bore Ia antigens. After incubation with J5 at 37°C, 80% of the CALLA+ cells no longer expressed either surface antigen or J5 antibody. However, these cells continued to express Ia antigen. In contrast, the Ia antibodies did not affect the expression of Ia antigen (Fig. 3C) . Using a larger panel of MoAb to analyze the J5-modulated cells (Table VII) , it was seen that the decrease in J5 reactivity was accompanied by a similar decrease in J13 expression. In contrast, only minor changes were seen in the expression of the non-CALLA-related antigens B1, J2, T10, and Ia even when the incubation period was extended to 48 h.
CFU-G/M Assays.
Previous studies using adult bone marrow or peripheral blood depleted of CALLA+ cells by J5 and complement (C) treatment have shown that such procedures did not selectively deplete this population of committed myeloid precursor cells (GFU-C, BFU-E, CFU-E, CFU-G/E) (25) . In Table VIII , data from experiments where different purified fractions of fetal liver and fetal bone marrow were tested for activity in CFU-G/M assays are shown. Irrespective of the tissue source and the method of purification, the CALLA+ cell fractions contained virtually no CFU-G/M. In contrast, most of the CFU-G/M could be recovered from the MoAb-rosette-negative and the CALLA-fractions. Since none of the antibodies used during the rosette depletion reacted with CFU-G/M, the low number of colonies in the MoAb-rosette positive fractions strongly indicate that very little nonspecific loss of CFU-G/M occurred during rosette depletion.
Discussion The series of experiments described in this study was designed to purify and characterize normal hematopoietic cells that express CALLA from fetal liver and fetal bone marrow, where they represent a relatively small fraction of the total rnononuclear cell population. A major reason for the success of the purification procedure was the initial MoAb-rosette depletion step, where R/M-SRBG were used to rosette leukocytes labeled with a mixture of MoAb against erythroid and myeloid differentiation antigens. In the subsequent rosette sedimentation, large numbers of erythroid and myeloid cells could be removed quickly and effectively. In this context, T9 antibody, which defines the transferrin receptor (20) was particularly helpful, because the majority of mononuclear cells in fetal liver suspensions, even after two F/H centrifugations, were normoblasts. In fetal bone marrow, the resulting rosette-negative cell suspensions were so enriched for CALLA+ cells that frequently these cells were >80% pure. Subsequently, further purification of CALLA+ cells was obtained either by cell sorting or by additional immune rosetting with J5 and J13 antibodies.
After purification, CALLA+ cells from both fetal liver and fetal bone marrow appeared to be a homogeneous population of medium-sized lymphocytes. However, with a series of monoclonal antibodies and immunofluorescence assays for intracytoplasmic-/~ and TdT, we have been able to demonstrate that the phenotype of CALLA+ cells is strikingly heterogeneous. This was found particularly when markers for immature B cells were used, because only ~40% of the cells were positive for the B1 differentiation antigen and 15-30% expressed cyto-# (Tables III and V) . Furthermore, only a minority (5-25%) of the CALLA+ cells contained TdT (Table V) . In contrast, virtually all CALLA+ cells expressed Ia, T10, and J2 antigens, and there were no major differences between cells isolated from fetal liver and fetal bone marrow. It should be noted, however, that some CALLA+ cells were also lost at each step of the purification procedure. For example, as shown in Table II , the MoAbrosette-positive population contained 2% J5+ cells, and the MoAb-rosette-negative, J5-rosette-negative population contained 3% J5+ cells. As these CALLA+ cells comprised very small fractions of these populations, they could not be accurately characterized. However, because these losses appeared to be nonspecific, we have assumed that the J5+ cells that were enriched and purified at each step are representative of the entire CALLA-positive population.
Earlier studies have demonstrated that leukemic cells from ~50% of patients with non-T ALL were reactive with B1 antibody (14) . When expression of B1 antigen was correlated with expression of CALLA, it was found that expression of B 1 was restricted to those tumor cells that were also CALLA+. Furthermore, recent studies using in vitro differentiation of ALL cells by phorbol diester showed that ALL cells which were CALLA+, B1-could be induced to express B1 surface antigen, whereas CALLA-ALL cells could not be induced to express B1 (26) . Taken together, this analysis of leukemic cells suggested that the majority of CALLA+ non-T ALL cells were derived from the B cell lineage and Ied us to predict that CALLA would be expressed at an earlier point in B cell development than B t. The analysis of CALLA+ fetal hematopoietic cells indicates that a large fraction of these cells are indeed in early phases of B cell development. In fact, the phenotype of normal CALLA+ cells is almost identical to that of CALLA+ leukemic cells, and, as has been suggested previously (4, 5) , these normal cells appear to be the normal counterpart of ALL cells. One major difference, however, is that only a small fraction of normal CALLA+ fetal lymphoid cells are TdT+, whereas almost all ALL cells contain this nuclear enzyme.
In addition to allowing a direct comparison of the surface markers of normal CALLA+ cells with leukemic cells, our purification of CALLA+ and CALLApopulations has allowed the identification of fetal lymphoid cells at different stages of maturation. It is evident that within the CALLA+ positive population at least three subsets can be identified. The first, and most differentiated, subset expresses both surface B 1 and cyto-bt , and therefore corresponds to a population that has previously been classified as "pre-B" cells (27, 28) . In addition, these cells express Ia, J2, and T10 antigens (as do all CALLA+ cells), but few of these cells appear to be TdT+. The second, less mature, subset has an identical surface phenotype (CALLA+, Ia+, J2+, T10+, BI+) but does not express cyto-~ or TdT. These cells appear to be at an earlier stage of lymphoid differentiation, but the expression of B1 suggests that they have already been committed to the B cell lineage. In studies noted previously (26) , ALL cells with this phenotype can be induced to express cyto-/~ with phorbol diester. The third subset of CALLA+ cells expresses Ia, J2, and T 10 but does not express B 1. The lineage of these cells is not clearly established by their surface phenotype because none of these antigens are lineage specific. Although a significant fraction of these cells is TdT+, most are TdT-. It is likely that some cells within this group are very early B cells that will subsequently express B 1 and then cyto-~ with further differentiation. However, the expression of CALLA is not restricted to B cells or B cell tumors because some T cell malignancies (T-ALL and lymphoblastic lymphoma) also express this antigen. It is therefore possible that some ceils within this group may be T cell precursors, with yet-undefined surface markers, that will later migrate to the thymus where further differentiation will occur.
Within the CALLA-cell fraction that was first depleted of mature erythroid and myeloid cells by immune rosetting and then further purified by removal of CALLA+ cells, our results also indicate considerable heterogeneity. Firstly, Giemsa-stained smears demonstrated that this fraction consisted of both large blast cells and small-to medium-sized lymphocytes (Fig. 1) . Approximately 60% were T10+, 55% were Ia+, 20% were J2+, and 15% were B 1 + (Table IV) . In addition, 35-50% of the CALLAcells were TdT+. It therefore seems likely that this fraction contains very early lymphoid precursor cells in addition to almost all myeloid precursor cells (here, CFU-G/M). Phenotypically, these cells appear to represent the nonmalignant counterparts of undifferentiated CALLA--ALL cells. The heterogeneity of the CALLA-fraction is further emphasized by the small but significant number of BI+ cells within this population. Because we did not test for expression of surface Ig, it is possible that some of these CALLA-, B 1 + cells are mature B cells. However, a small but significant percentage of CALLA-cells also express cyto-#, and it is therefore evident that not all pre-B are contained within the CALLA+ population. Recent clinical studies also support the conclusion that the most immature stem cells (both myeloid and lymphoid) do not express CALLA. In these studies, patients with CALLA+ ALL in second remission received ablative chemotherapy and total body irradiation followed by infusion of autologous bone marrow that had been depleted of CALLA+ cells (both normal and leukemic) by in vitro treatment with J5 antibody and C (29) . All patients thus far have been engrafted with antibody-treated bone marrow, and two patients who have been followed for >1 yr have demonstrated complete reconstitution of all myeloid and lymphoid populations.
Earlier studies using CALLA+ leukemia cells and cell lines have shown that J5 antibody induces antigenic modulation of cell surface antigen (8) . This phenomenon has had important implications for the passive serotherapy of patients with ALL because J5 antibody infusions lead to loss of CALLA expression on malignant cells without impeding their growth (9) . The data presented in Fig. 3 and Table VII demonstrate that modulation of CALLA by J5 antibody is a physiologic phenomenon that occurs on normal CALLA+ ceils as well. Thus, whereas CALLA modulation may be a mechanism whereby leukemic cells may become resistant to antibodymediated lysis, the modulation of CALLA on fetal cells may be indicative of a normal functional property of this cell surface glycoprotein. Other surface molecules that undergo antigenic modulation such as surface Ig (30), C3b receptor (31); and T3 antigen (32) appear to have specific membrane receptor-like functions; CALLA modulation may therefore be analogous to the phenomenon of "down-regulation" in which expression of cell surface receptor is decreased in the presence of excess ligand or hormone (33, 34) .
Summary
Fetal hematopoietic cells that express the common acute lymphoblastic leukemia antigen (CALLA) were purified from both fetal liver and fetal bone marrow by immune rosetting with sheep erythrocytes coated with rabbit anti-mouse immunoglobulin and by fluorescence-activated cell sorting. Dual fluorescence techniques disclosed that these cells were heterogenous with respect to the expression of a series of differentiation and activation antigens defined by monoclonal antibodies. Thus, whereas all CALLA+ cells were Ia+ and expressed two activation antigens, J2 and T10, only 30-50% expressed B 1 antigen. Furthermore, using methanol-fixed cells, it could be shown that ~20% contained intracytoplasmic ~ chains (cyto-/l) and that 15% were positive for the terminal transferase enzyme (TdT) marker. The CALLA+ fetal cells thus closely resemble the childhood acute lymphoblastic leukemia cell with respect to surface marker phenotype. A population of CALLA--cells devoid of mature erythroid and myeloid surface markers was found to contain higher numbers of TdT+ cells but lower numbers of cyto-#, B1, and Ia+ cells than the CALLA+ subset. In 
